• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Expert Views: Stem Cells as Clinical and Research Tools For COVID-19

Expert Views: Stem Cells as Clinical and Research Tools For COVID-19

0
By Biotech Express on May 18, 2020 Articles, Articles- Guestorials, SARS- CoV2 & COVID-19 Updates

by S. Dravida, PhD
Founder and CEO, Transcell Biologics

World Health Organization (WHO) has named SARS-CoV2 (a new format of corona virus) as COVID-19 while declaring it as causative agent of the pandemic outbreak in 2020 with roots from China. According to a recent publication of the International Society for Stem Cell Research (ISSCR), currently, there are no approved stem cell-based approaches neither for prevention nor treatment of COVID-19 infection. Mesenchymal stem cells (MSCs) are being researched and trialed as one of the therapeutic tools in the treatment of COVID19. The hypothesis on which MSCs are being trialed is that this particular stem cell type opposes viral infection due to the secretion of specific cytokines by them. These ancillary secretory components are present in MSCs in their intrinsic forte and so they survive even if they are transplanted into a patient with a confirmed COVID-19 infection.

 

About Author  

S Dravida leads the team and collaborations responsible for discovering druggable formulations across therapeutic areas and platforms. Her role requires converging and executing both laboratory, clinical research programs across touch points. Her Past Affiliations include University of North Carolina, Ottawa Health Research Institute and Center for Cellular and Molecular Biology, Hyderabad Eye Research Foundation. Expertise: Adult stem cell technologies, Predictive platform development and screening, Primary cells, Tumorospheres, Low throughput and High throughput platform technologies, Cancer progenitor cells, Repository of patient sourced screening platforms, Cell based readouts, Drug discovery, pre-discovery process etc.

 

 

COVID-19 is shown to trigger a destroying immune overreaction in the body while the immune system produces large amounts of inflammatory factors, causing a cytokine storm that includes an overproduction of immune cells and cytokines. MSCs are postulated to prevent the storm release of cytokines by the immune system and stimulate endogenous repair by reparative properties owing to their stemness. Typically, after intravenous injection, portion of the injected MSCs entangle in the lung, which in otherwise systemic infusion is perceived as a limitation, while it is a blessing in disguise for COVID-19 patients that could positively influence the recovery in the pulmonary microenvironment by way of protecting alveolar epithelial cells, intercepting pulmonary fibrosis, and ultimately curing lung dysfunction and pneumonia caused by the virus.

Adult stem cells especially MSCs can be handy to mimic the human host environment when modeling viral pathogenesis invitro. Noroviruses, rotaviruses, enteroviruses, adenoviruses, zika virus and many other viruses were studied by infecting stem cell cultures invitro while genome-wide analysis of host-virus crosstalk, identification of host factors critical for viral pathogenesis, and the study of viral pathogens are some of the lab based research findings supporting the discovery and development of solutions to diagnose and cure viral diseases. Human biological discards sourced MSCs could be an ideal stem cell type for invitro infection studies with COVID-19 strain while addressing the otherwise known challenges dealing with biopsies, availability, ethics etc.

MSCs type has attracted attention to be considered as therapeutic tool for COVID-19 infection due to source availability, their high proliferation rate supporting in culturing in the labs, low invasive procedure when being injected, and with no ethical issues. As MSCs can be stored for repetitive therapeutic usage, biobanks could play a quintessential role in the supply with safety and efficacy of MSCs documented in several clinical trials.

Pathological microenvironment induced by viral infections in cell cultures contribute tremendously to a researcher’s work on host-virus interactions. If the cell cultures are harvested from human system, they become an amazing alternative invitro systems that accurately re-create in vivo human physiology that can support the study of viral pathogenesis.

About Transtoxbio
Transtoxbio (www.transtoxbio.com) is a portfolio with all new league of human biological discards sourced (ethically immuned) primary progenitor cell based platforms for specialty next generation invitro applications in preclinical basic and translational research. Primary stem cells are amenable to any research specific modelling and are cost-effective in the scheme of operations with relevant human specific read outs obtained as experimental end points.

Reference:
1. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future [published online ahead of print, 2020 Apr 13]. Stem Cell Rev Rep. 2020;1‐7. doi:10.1007/s12015-020-09973-w
2. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging and disease 2020, Vol. 11. Issue (2) : 216-228 DOI: 10.14336/AD.2020.0228

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.